Navigation Links
Controversies in science and technology explored in new book from Mary Ann Liebert
Date:2/19/2008

New Rochelle, NY, February 19, 2008Controversies in Science and Technology, Volume 2: From Climate to Chromosomes presents an in-depth exploration of hot topics in modern science and technology that is accessible to a broad audience. The book takes a unique approach, using multiple experts of diverse and often clashing viewpoints to explore each of the volumes five topicsStem Cell Research, Information Technology, Space Exploration, Global Warming, and Biology and Gender. This book fills an important gap in offerings on science and technology, providing scientists, social scientists, and the lay public with in-depth analysis of issues that confront every citizen of the earth. The provocative essays are engaging and well-written, enabling the reader to hear original voices in each debate. This new book was just published by Mary Ann Liebert, Inc.

In a world that is increasingly dependent on technology, where the pace of science is constantly accelerating, and even experts are flummoxed by many of the decisions that confront us, this volume is welcome and needed. Its essays simultaneously educate and challenge the reader by providing the scientific, religious, public policy, and societal issues presented by the latest, groundbreaking technological advances. These essays provide sufficient background and diversity of opinion to enable a reader to form reasoned opinions and make informed decisions, thereby empowering the reader to join in the public debate.

The section on Stem Cell Research, for example, presents the surprising biological insight that embryonic stem cells are not from embryos, but derive from a primitive clump of cells known as a blastocyst, inviting the reader to wonder whether the debate would have been different if scientists had announced that they had grown blastocyst cells in culture. The essays also offer the ethical perspectives on stem cell technology of the Catholic Church, Judaism, and Islam. Information Techno
'/>"/>

Contact: Vicki Cohn
vcohn@liebertpub.com
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Politics has taken notice of science
2. Novel organic metal hybrids that will revolutionize materials science and chemical engineering
3. UNT Health Science Center and The Center for Cancer and Blood Disorders Collaborate on New Institute for Cancer and Blood Disorders
4. Accipiter Life Sciences Announces Nomination of Three Independent Director Candidates for Election to the Penwest Board at the 2008 Annual Meeting
5. European Neuroscience and Society Network tackles neurosocieties head-on
6. Cardiac Science to Present at the Roth Capital Partners 20th Annual Growth Stock Conference
7. Edwards Lifesciences Initiates Patent Infringement Litigation Against CoreValve in the U.S.
8. DARA BioSciences, Inc. and Point Therapeutics, Inc. Announce Consummation of Merger
9. ScienceBased Health Appoints Anne L. Coleman, MD, PhD to Scientific Advisory Board
10. SpectraScience, Inc. Retains Hayden Communications
11. Pennsylvania Gov. Rendell: $10 Million Partnership With Harrisburg Venture Capital Firm Boosts PAs Life Sciences Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/6/2008)... WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- ...nst several companies alleging that they,submitted...kbacks and the,establishment of sham durable medic...nt announced today. The companies are McKesson Cor...MediNet), GGNSC Holdings LLC,Golden Gate Ancillar...
(Date:10/6/2008)... A study led by researchers at the University of ...that use of oral Vitamin D supplements bolsters pr...n the skin, and may help prevent skin infections t...most common form of eczema. , The study led by ...and chief of the Division of Dermatology at the UC...
(Date:10/6/2008)... SAN DIEGO, Oct. 6 /PRNewswire/ -- Developed in... of Pacific Palisades, CA is introducing,Revolutio...y into the,Plastic Surgery office of Dr. Steve Lav... XS-300(TM), is the first of its kind, and is base...hnology combined with,innovative proprietary softw...
(Date:10/6/2008)... Vision Audio Inc. has an...deo game designed to help train children with auti...Se Off-Road is a fun, non-violent learning experie...participate in their enhanced sound-based therapy,...dio ( http://www.easecd.com ). , ...
Breaking Medicine News(10 mins):Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Oral vitamin D may help prevent some skin infections 2Health News:Plan Your Breasts in 3-D 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 3
...me up with a novel idea to boost up the sales of t...are. He has announced a handsome reward of Rs. 100...ate.// "No bird flu case has been registered in t...mport has been banned in the state. We offer a rew...
...vaccinated against diphtheria-tetanus-pertussis. T... causes a red splotch to develop on the area. Thi...that// neither of two common drugs--ibuprofen (Adv...prevent this side effect. A Group Health Cooperati...
... as about 3,000 people in the steel town were affe...irst reported in a small group at a slum// cluster...or its steel plant, Monday. Since then, it has rap...of the town. The high fever is accompanied by vom...
...that stem cell therapy for heart attack may not be...under rigorous conditions//. German researchers ha... improve cardiac function following heart attack. ...ics have had the potential to attract the attentio...
Other Medicine News:Health News:Allergic reaction to DTaP vaccine persists in children 2Health News:Stem Cell Therapy For Heart Attack Found To Be Ineffective 2
(Date:10/6/2008)...with Durezol Dosed Prior to Surgery, TAMPA, Fla.,... a,privately held ophthalmic-focused biopharmaceut...fluprednate ophthalmic emulsion) 0.05% is now,comm... the U.S. Food and,Drug Administration in June 200...d for the treatment of inflammation and pain assoc...
(Date:10/6/2008)...e to severe patients achieved endoscopic,response ...sion at Week 10,in data from a 54-week open-label ...nterology (ACG) Annual Scientific Meeting, ORLAND...d data from a,large, prospective study investigati...with a biologic compound. The data presented at th...
(Date:10/6/2008)...stCall/ -- Dendreon Corporation (Nasdaq:,DNDN) wil... 2008 at 9:00 AM,ET (6:00 AM PT) to review the out...therapy for Prostate AdenoCarcinoma Treatment, als...sipuleucel-T), the Company,s investigational,activ...nced prostate,cancer., Those interested may ac...
(Date:10/3/2008)...s the newest study site, PHILADELPHIA, Oct. 3 /PR... Philadelphia today received a contract to manage ... Children,s Hospital will manage local,participati...County, New,Jersey. The study is funded by the Nat...pate approximately 1,000 families in Burlington,Co...
Breaking Medicine Technology:Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 2Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 3Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 4Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 5CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 2CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 3CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 4CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 5CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 6CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 7Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial 2The Children's Hospital of Philadelphia Announces New Regional Participant in The National Children's Study 2Abbott Receives FDA Approval for SIMCOR 28R 29 28Niaspan 28R 29 simvastatin 29 a Novel Combination Medicine for Comprehensive Cholesterol Manageme 3343 1Abbott Receives FDA Approval for SIMCOR 28R 29 28Niaspan 28R 29 simvastatin 29 a Novel Combination Medicine for Comprehensive Cholesterol Manageme 3343 2Abbott Receives FDA Approval for SIMCOR 28R 29 28Niaspan 28R 29 simvastatin 29 a Novel Combination Medicine for Comprehensive Cholesterol Manageme 3343 3Abbott Receives FDA Approval for SIMCOR 28R 29 28Niaspan 28R 29 simvastatin 29 a Novel Combination Medicine for Comprehensive Cholesterol Manageme 3343 4Abbott Receives FDA Approval for SIMCOR 28R 29 28Niaspan 28R 29 simvastatin 29 a Novel Combination Medicine for Comprehensive Cholesterol Manageme 3343 5Abbott Receives FDA Approval for SIMCOR 28R 29 28Niaspan 28R 29 simvastatin 29 a Novel Combination Medicine for Comprehensive Cholesterol Manageme 3343 6Stress may increase a womans risk of developing cervical cancer 12083 1Stress may increase a womans risk of developing cervical cancer 12083 2Daily Stress May Raise Womens Risk of Cervical Cancer 12080 1Daily Stress May Raise Womens Risk of Cervical Cancer 12080 2Daily Stress May Raise Womens Risk of Cervical Cancer 12080 3A map of the worm 3A First detailed anatomical atlas of C elegans for use in the lab 12077 1A map of the worm 3A First detailed anatomical atlas of C elegans for use in the lab 12077 2
...ease Week -, CAMBRIDGE, Mass., May 21, 2007 /PRNew...n of data from a Phase 2 study in which,linaclotid...unction,in patients with constipation- predominant... showed linaclotide was well tolerated with,a low ...t-in-class,compound currently being developed for ...
...rom phase III,clinical trials and further human ph...ress of the European Academy of,Dermatology and Ve...acy and safety profile of alitretinoin as a potent...vere refractory chronic,hand eczema. , Currently, ...nd,Eczema (CHE) refractory or unresponsive to topi...
Other Medicine Technology:Microbia Announces Positive Phase 2 Results for Its Investigational,Compound Linaclotide 2Microbia Announces Positive Phase 2 Results for Its Investigational,Compound Linaclotide 3Microbia Announces Positive Phase 2 Results for Its Investigational,Compound Linaclotide 4Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress 2Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress 3Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress 4Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress 5
Helmer's Horizon Series Plasma Storage Freezers HPF 125-4 incorporate solid performance and value. They feature a microprocessor-based independent temperature controller and alarm/monitor system with
Plasma Blast Chest Freezer -50C - 8098/8091 maintains a -50C (-58F) temperature to rapidly freeze single donor, apheresed, and fresh frozen plasma. Rapid freezing also preserves Factor VIII. Full loa
...for digital histology. It consists of a scanner, a...software modules. At the heart of MIRAX SCAN lies ...s Digital Slides. Any time, from any place. In bri...s on a microscope. The Digital Slide will revoluti...
... incorporates detection of T-wave alternans (TWA) ...nalysis tools. Premier 12 makes a complete 24-hour... provides visualization of the actual TWA, for vis... detects two modes of TWA: the beat-to-beat change...
Medicine Products: